FDA Rejects Gefapixant NDA for Chronic Cough
The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Merck regarding the New Drug Application for gefapixant for the treatment of adults with refractory or unexplained chronic cough.
Gefapixant is an orally administered, selective P2X3 receptor antagonist. The application included data from the two phase 3 studies, COUGH-1 (ClinicalTrials.gov Identifier: NCT03449134) and COUGH-2 (ClinicalTrials.gov Identifier: NCT03449147), which evaluated the efficacy and safety of gefapixant in adults with refractory or unexplained chronic cough for at least 1 year.
In the CRL, the FDA requested additional information related to measurement of efficacy. The letter was not related to the safety of gefapixant.
“We remain committed to advancing gefapixant for patients with refractory or unexplained chronic cough and will work with the FDA to address the agency’s feedback,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.
Lees dit bericht verder op: FDA Rejects Gefapixant NDA for Chronic Cough – MPR (empr.com)
